Strength, Gratitude, & Heroes

Prostate Cancer Foundation
Curing Together.

2019–20 Annual Report
Mission Statement

PCF funds the world's most promising research to improve the prevention, detection, and treatment of prostate cancer and ultimately cure it for good.

Strength, Gratitude, & Heroes

There is no doubt about it: 2020 started in an unexpected way. A new enemy emerged, and it made us that much more thankful for old friends and family. Whether your hero is your dad, your doctor, or your spouse, this is the time for a renewed investment in gratitude for both small moments and monumental achievement.

2019 saw 3 new FDA approvals for prostate cancer. Two more arrived in 2020, and an additional approval is expected later this year. At PCF, we continue to fight prostate cancer without reservation. Our mission is to ensure that families have more days together and -- as with every challenge we rip through at PCF -- science will prevail in these trying times.

Thanks to the generous donations of people like you, more than 600 PCF researchers at nearly 100 institutions are actively using cutting-edge science to discover new therapies and solve the toughest prostate cancer problems to keep you safe, for a long time to come.
<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Message From our President and CEO</td>
<td>4</td>
</tr>
<tr>
<td>PCF in 2019: By the Numbers</td>
<td>8</td>
</tr>
<tr>
<td>Early Investment Hits the Jackpot</td>
<td>10</td>
</tr>
<tr>
<td>PCF Fundraising Community</td>
<td>12</td>
</tr>
<tr>
<td>Renowned Actor Harry Lennix Teams With PCF for National Minority Health Month</td>
<td>14</td>
</tr>
<tr>
<td>The NBA Doubles Down on Assisting Men With Prostate Cancer</td>
<td>15</td>
</tr>
<tr>
<td>Finding Prostate Cancer Earlier... and (Much) Earlier</td>
<td>16</td>
</tr>
<tr>
<td>Extraordinary Care for Veterans</td>
<td>18</td>
</tr>
<tr>
<td>Leveraging Relationships and Passion Into Research Dollars</td>
<td>20</td>
</tr>
<tr>
<td>Movember: Accelerating Science Together</td>
<td>22</td>
</tr>
<tr>
<td>The Jerry II: Golf for Good – Honoring a Hollywood Legend</td>
<td>23</td>
</tr>
<tr>
<td>2019 Home Run Challenge: The Dickson Family and PCF Team Up for a Cure!</td>
<td>24</td>
</tr>
<tr>
<td>A Patient’s Journey: Sheffler Strong</td>
<td>26</td>
</tr>
<tr>
<td>Accelerating Women in Science</td>
<td>28</td>
</tr>
<tr>
<td>PCF Catalyzes the Development of a Polygenic Test for African American Men at Highest Risk</td>
<td>29</td>
</tr>
<tr>
<td>Supporting Cures</td>
<td>30</td>
</tr>
<tr>
<td>2019 Donor Roll</td>
<td>31</td>
</tr>
<tr>
<td>2019 Research Awards</td>
<td>38</td>
</tr>
<tr>
<td>2019 Financials</td>
<td>42</td>
</tr>
<tr>
<td>2019 Supporting Partners</td>
<td>46</td>
</tr>
<tr>
<td>Board of Directors and Leadership Team</td>
<td>47</td>
</tr>
</tbody>
</table>
Dear friends,

We hope that you are safe and well. Prostate cancer has not stopped in the pandemic, and neither has PCF.

All over the world, lives have been completely changed. Many people have lost jobs, familiar routines, financial security — even loved ones — to the virus. But for those battling prostate cancer during this time, the changes can present an entirely different level of complication and anxiety.

Since the moment this crisis began, PCF has been working 7 days a week, adjusting our priorities, to best serve the patients and families who look to us for information and breakthrough advances in treatment. Over 15 PCF-funded researchers and teams pivoted to work on projects aimed at preventing deaths from COVID-19 using their deep expertise on how to fast-forward anti-COVID-19 drugs.

Here’s just one example. In January, German scientists discovered that one of the ways SARS-CoV-2 fatally infects the lungs is by using a “door handle” protein called TMPRSS2. This receptor protein is required for the coronavirus to enter lung cells. TMPRSS2 is also a key drug target in prostate cancer bone metastasis and has received millions of dollars of PCF research funding starting in 1998 and right up through 2020. Because TMPRSS2 is a longstanding PCF drug research target (over 900 publications), in just under 4 weeks, thanks to round-the-clock Zoom meetings and emails, multiple prostate cancer researchers in the PCF research enterprise collaborated with infectious disease experts to test their anti-TMPRSS2 drug approaches against COVID-19. This occurred globally in PCF laboratories and with breathtaking speed in emergency clinical trials in the U.S., Denmark, Italy, Japan, Germany, and Great Britain.
As we continue to fund the life-extending and life-saving research that is so urgently needed by prostate cancer patients, we’ve simultaneously shifted our focus in some other very targeted ways, to do our part to help our patients and our healthcare workers get through this crisis, safely. Here are just a few actions PCF has taken to help patients weather this storm:

1. **Returning patients to their treatment plan.** Until our hospitals and clinics are safe for health care workers, they’ll never be safe for you and me. PCF-funded Young Investigator Dr. James Byrne, who has both an oncology and engineering background, is part of team of scientists at MIT who have rapidly redeployed their skills to build a better mask for COVID-19, fast. Dr. Byrne and team have developed a way to cheaply mass-produce masks that can be re-sterilized by basic methods. This is an important step in ensuring healthcare providers have the protection they need to treat prostate cancer patients. Eventually, we hope this mask would be available to anyone visiting a health care facility, including patients and caregivers. Learn more at [join.pcf.org/mask](http://join.pcf.org/mask).

2. **Providing the most up-to-date, targeted information about COVID-19 for prostate cancer patients.** [pcf.org/COVID-19](http://pcf.org/COVID-19) is updated constantly with information about how your treatment may change during the pandemic. This includes Facebook LIVE broadcasts with me, podcasts with Mike Milken, and conversations with some of our researchers on the front lines, including medical oncologists Dr. Alicia Morgans and Dr. Tanya Dorff. We’re still learning about the COVID-19 disease, day by day, and PCF is bringing this information to our audience of patients and families in real time.

3. **Keeping our researchers working.** Mentorship is a hallmark of PCF’s success with breakthrough research. We fund many incredible young investigators (YIs) who are thinking outside the box on how to attack prostate cancer – and even COVID-19 (see above). Some are looking to us for extra mentorship as they navigate trying to do research in this storm – even just to keep their experiments going. Others are directly caring for COVID-19 patients. Our science team, led by Chief Science Officer Dr. Howard Soule, has reached out (digitally!) to all of our YIs to offer support, advice, or just listen. We want them to hit the ground running when this crisis passes.

4. **Focusing on patient care.** The most respected resource patients have is the [PCF Prostate Cancer Patient Guide](http://pcf.org), edited by 15 of the world’s leading clinicians. This free roadmap of how to deal with your prostate cancer treatment and recovery, no matter the stage, has been hailed by patients and doctors alike as a must-have. Although we will delay releasing a new printed version of the guide until this pandemic subsides, we will continue our commitment to update the guide for download at least 2 times per year, making it truly the most current and comprehensive resource you can get on prostate cancer. We recently released our first update of 2020: an appendix dedicated entirely to “Your Care During the COVID-19 Pandemic,” including specific notes for every stage of the prostate cancer journey.
At the same time as this extraordinary work is continuing, we acknowledge that there are even more unprecedented real-world problems created by this pandemic. Today, as I write this letter, we are getting emails from men newly diagnosed with prostate cancer who are scared because their treatment is being delayed. It’s not easy, but we take some solace in the fact that many of these men will still have a good outcome – in part because prostate cancer is slow-growing, and in part because, over the years, PCF-funded advances in science have multiplied the number of treatment options that will be available when things return to normal.

In fact, 2019 was one of the most prolific years for new drug advances and approvals, bringing us a giant step closer to achieving PCF’s mission to ending all death and suffering from prostate cancer. The U.S. prostate cancer death rate decreased again by another 3.1%. Compared with the year Mike Milken was diagnosed and founded PCF, the death rate has been reduced by 52.2%. Simply put: vastly more men are alive.

Translating PCF research from concept to clinic does not happen overnight – it takes years of team collaboration, individual creativity, and grinding work in the lab. 2019 was a remarkable year in terms of the number of practice-changing medicines to help patients. This is the ultimate metric of progress in cancer research. In total, PCF funded the earliest stage R+D for 7 such changes (including 3 new FDA approvals):

1. **Apalutamide**: FDA-approved for men with metastatic prostate cancer that is responsive to hormone therapy. In a clinical trial, this drug lowered the risk of death by 33%.

2. **Enzalutamide**: FDA-approved for men with metastatic hormone-sensitive prostate cancer. Compared with placebo, men taking enzalutamide were 33% less likely to die.

3. **Darolutamide**: FDA-approved for men with prostate cancer that is not responsive to hormone therapy and with no visible metastases upon imaging. The drug more than doubled the time men lived without metastasis.

4. **Cabazitaxel**: shown to slow cancer growth in men with metastatic disease that is resistant to hormone therapy and who have progressed on other treatments – a patient population that has historically had few options.

5. In a demonstration of the power of precision oncology, the drug **olaparib** was shown in a clinical trial to delay disease progression or death compared with standard-of-care treatments.
6. A new understanding of metastatic disease and a new use of radiation therapy in men with a low number of metastases showed that focused radiation directed to the metastases resulted in lower rates of progression.

7. Sometimes, the best treatment is less treatment. A fresh look at data from a large randomized trial revealed that among patients with recurrent prostate cancer receiving radiation therapy, PSA can be used to determine which men need hormone therapy as well. If the PSA is low, no hormone therapy is needed.

Beyond research, 2019 was also the greatest year ever for outreach to men with prostate cancer, with our patient education and communications efforts extending further than any other year in PCF’s history:

- Web traffic increased 30% and social traffic increased by 200%
- Over 100,000 informational guides distributed
- Creation of a new guide for the whole family, The Science of Living Well, Beyond Cancer
- Over 500 pieces of public-facing content created, including articles, blog posts, videos, social media posts, patient stories, and direct emails to patients and families
- 37% increase in new donors who gave from $5 to $1,000,000
- PCF’s awareness campaign, “Light It Blue,” touched the entire country: in September 2019, all 50 states had at least one building lit blue for Prostate Cancer Awareness Month

Inside, you’ll find a look back at a scientifically stunning 2019, and a look forward at 4 groundbreaking research thrusts we’re working towards globally in 2020: 2 new precision medicines that target weaknesses in tumor cells; new imaging technology with the promise to detect smaller cancers earlier; and a new saliva test to assess a man’s lifetime prostate cancer risk.

Thank you for your enduring interest in ending death and suffering from prostate cancer. Please stay safe, cheerfully distant, and digitally close – and where possible – give those you love an extra tight hug.

In service,

Jonathan W. Simons, MD
President and Chief Executive Officer
PCF IN 2019
BY THE NUMBERS

improvements funded in standard-of-care- or paradigm-changing clinical trials, elevating the standard of care for patients with advanced metastatic disease

205 impactful PCF-funded researcher publications

558 multi-disciplinary researchers collaborating at PCF’s Annual Scientific Retreat

17 Challenge Awards
30 Young Investigator Awards
8 PCF VAlor Awards
38 First-time Awardees

Breakthroughs in Prostate Cancer Treatment and Practice

1993
PCF founded by philanthropist Michael Milken

1994
FDA approves PSA test for PC screening

1996
Discovery of inherited genes in familial PC

1999
First PCF liquid biopsy science conference

2000
First robotic surgery system approved by FDA

2003
First human genome sequenced

2004
Docetaxel FDA-approved for mCRPC

2007
IGRT becomes standard of care for radiation therapy
52% DECLINE IN DEATHS FROM PROSTATE CANCER SINCE PCF’S FOUNDING

77,871 PCF-published Prostate Cancer Patient Guide copies distributed to ensure that men and their families have access to the most comprehensive, updated information available.

3 FDA drug approvals with early-stage funding from PCF

500+ pieces of content created to raise awareness and help patients and caregivers better navigate their journey.

2018-2020 FDA Approvals Explode!

2018
- Enzalutamide FDA-approved for nmCRPC
- AR-V7 blood test available
- Germline genetic testing added to NCCN guidelines
- Abiraterone FDA-approved for mHSPC
- Apalutamide FDA-approved for nmCRPC

2019
- Darolutamide FDA-approved for nmCRPC
- Prostate EBRT+ADT standard of care for low-vol. mHSPC
- Apalutamide, enzalutamide FDA-approved for mHSPC

2020
- Olaparib, rucaparib FDA-approved for mCRPC
- 68Ga-PSMA-11 PET imaging FDA-approved*

* Anticipated approval
In May 2020, the FDA approved 2 drugs, rucaparib and olaparib, for prostate cancer treatment. These milestone achievements can be directly traced to research funded by the Prostate Cancer Foundation (PCF).

Rucaparib and olaparib are PARP inhibitors, a new class of therapies that are used to treat breast and ovarian cancer with BRCA1 or BRCA2 gene mutations. BRCA1 and BRCA2 are critical “DNA repair” genes, which mend broken DNA. In order to survive, cancer cells with mutations in BRCA1 or BRCA2 become dependent on an alternate DNA repair protein – PARP. This Achilles’ heel causes BRCA1/2-mutant cancer cells to be sensitive to PARP inhibitors.

The BRCA1/2 mutant genes were first discovered in association with increased risk of breast and ovarian cancer in women; Angelina Jolie publicly shared her story of undergoing prophylactic surgery in 2013. However, PCF-funded studies demonstrated that BRCA1/2 and PARP are also important in prostate cancer.

A team funded by a 2012 Movember-PCF Challenge Award and led by Dr. Karen Knudsen of Thomas Jefferson University provided early preclinical evidence that PARP is important in prostate cancer and that PARP inhibitors may have promise as treatments.

In 2015, the PCF International Prostate Cancer Dream Team, led by Dr. Arul Chinnaiyan, of the University of Michigan, and Dr. Charles Sawyers, of Memorial Sloan Kettering Cancer Center (MSKCC) demonstrated that up to a quarter of metastatic castration-resistant prostate cancers (mCRPC) have mutations in BRCA1, BRCA2, or other related DNA repair genes. In about half of men with BRCA2 and BRCA1 mutations, the mutations were inherited (see box next page).
The PCF Dream Team, led by Dr. Johann de Bono of the Institute of Cancer Research and Royal Marsden NHS Foundation Trust, initiated a Phase II clinical trial, which demonstrated that olaparib was an effective precision medicine treatment in some prostate cancer patients, particularly those with DNA repair gene mutations.

These findings inspired a race among several pharmaceutical companies to test their PARP inhibitors in prostate cancer clinical trials – 2 of which have been completed and are now under FDA review.

The randomized Phase III PROfound trial, led by Dr. de Bono and PCF-funded investigator Dr. Maha Hussain of Northwestern University Lurie Cancer Center, tested olaparib versus physician’s choice of abiraterone or enzalutamide in mCRPC patients with DNA repair gene mutations who previously progressed on abiraterone or enzalutamide. The Phase II TRITON2 trial, led by 2015 David H. Koch-PCF Young Investigator Dr. Wassim Abida, of MSKCC, tested rucaparib in mCRPC patients with DNA repair gene mutations who had previously progressed on androgen receptor-directed therapy and chemotherapy.

Both trials demonstrated that PARP inhibitors are effective in mCRPC patients with mutations in BRCA1/2 and several other DNA repair genes. However, it is not yet clear which DNA repair gene mutations beyond BRCA2 indicate sensitivity to PARP inhibitors. BRCA2 is the most commonly mutated DNA repair gene in mCRPC, present in approximately 8%-12% of patients.

Other PARP inhibitors currently in Phase III prostate cancer clinical trials include talazoparib and niraparib. Trials are also testing PARP inhibitors in all prostate cancer patients (regardless of DNA repair gene mutations) and in combination with other treatments.

The Prostate Cancer Foundation is proud to have funded the foundational studies that have delivered these 2 new precision medicine treatments for advanced prostate cancer.

**PCF-funded studies** have demonstrated that approximately 12% of men with metastatic prostate cancer have inherited mutations in DNA repair genes (most frequently in BRCA2) which likely caused their cancer. National Comprehensive Cancer Network (NCCN) guidelines now recommend that all men with high risk, regional, or metastatic prostate cancer undergo genetic testing for inherited mutations in BRCA1/2 and related genes. Men found to be carriers may be not only be candidates for PARP inhibitor treatment, but this is also critical information for their families. Mutations in these genes are associated with increased risk for ovarian, breast, prostate, pancreatic, and potentially other cancers. Both male and female family members of carriers are highly encouraged to talk with their physicians about genetic counseling and their own cancer risk and recourse.
PCF Fundraising Community

Men and Women Across the Country are Helping Realize PCF’s Mission in their Local Communities

Caregivers, survivors, family, friends, and fighters are joining together with one focus: eradicating prostate cancer. Together, PCF community members have raised more than $2 million for prostate cancer research through a variety of local events and activities.

One observation we often hear from families who have been affected by cancer is “I feel powerless against this disease. What can I do to help?” PCF community members are leading the way, showing that anyone and everyone can make a difference in the fight against cancer. Fundraising for PCF helps bring awareness to each of our social circles, and PCF provides easy-to-use tools to activate your network in support of prostate cancer research.

Please visit pcf.org/fundraise today to learn more and join our community.

Stephen Tendrich Leads the Pink Nail Society

Stephen Tendrich was working as a bartender on Fire Island when he received a call from his father, Donald. Although he had been battling prostate cancer for years, this was the first time Donald decided to admit to Stephen that his surgery had made him feel less like a man. Stephen knew he had to do something about it. “I decided to paint my nail pink and show him, ‘Hey Dad, I’m still a man with nail polish!’” Stephen chose pink because it is a color that men are not typically comfortable with. Similar to talking about prostate cancer, he saw it as a challenge for men to step outside their comfort zone.

Stephen has since built a vibrant community through the Pink Nail Society and raised over $15,000 for PCF’s mission by hosting local events, including an 80s Prom Night with over 200 attendees. Today, Donald has no detectable cancer. But Stephen has no plans to slow down – he is continuing to raise awareness and empathy for prostate cancer in the LGBTQ community of South Florida, and to accelerate PCF’s science through his outstanding fundraising.
The Updegraves Tackle the AT

What can you accomplish when you set your mind to it? For Dave Updegrave and his sons, Ben, Luke and Cale, the answer is "quite a lot"! These 4 fearless men from Pennsylvania set out to through-hike the Appalachian Trail from Georgia to Maine, conquering 2,200 miles on foot. They wanted "to honor our many friends that have battled and are battling" prostate cancer, and raised over $3,400 for PCF.

Tyler Runs for his Dad

How do you show support for someone impacted by prostate cancer? How can you honor their experience and "do something about it"? For Tyler Holden, the answer came in the form of long-distance running. He took on the Cape Cod Half-Marathon, running 13+ miles and raising over $1,800 in honor of his dad.

Becky Brings Awareness and Action to Chicago

Kevin Wegner was a beloved father and friend. When he passed away from prostate cancer he was sorely missed. To honor his memory, his daughter, Becky, organized her first ever fundraising event, The End of an Era, gathering over 200 friends and family members for a fun Roaring 20s-themed event in Chicago that raised nearly $10,000 to accelerate the science to eradicate prostate cancer.

It takes more than one person to end prostate cancer.
It takes a community. Together, we are making a difference!
In 2019, Harry Lennix, star of the NBC series, “The Blacklist,” joined PCF as a celebrity ambassador. Harry kicked off his work with a PCF public service announcement, filmed on the set in the FBI Counterterrorism Division’s office, where Lennix plays Assistant Director Harold Cooper.

Thanks to the generosity of Comcast NBCUniversal and PCF Board member Neal Rodin, the PSA had over 9 million viewings across all 50 states.

“If we give a damn about the people that we love, then we have to be here for them. And if by going to get a test once a year, get our blood drawn, if that can help – by all means, we have an obligation to do it, and it need not be feared.”

— Harry Lennix
The NBA Doubles Down on Assisting Men With Prostate Cancer

African American men are 75% more likely to get prostate cancer and over twice as likely to die from it. February 2020 launched the second annual Black History Month Assist Challenge, an initiative focused on raising awareness of disparities in prostate cancer while raising funds to support life-saving research.

In 2019, the Atlanta Hawks were the first team in the NBA to partner with PCF. This year, the Brooklyn Nets, Chicago Bulls, Detroit Pistons, Indiana Pacers and Philadelphia 76ers joined the returning Hawks to create an all-star team dedicated to educating thousands of sports fans.

Throughout February, teams donated to PCF through a variety of methods, such as $250 for every assist, $50 for every field goal, and 50/50 raffle earnings. Proceeds will be added to the over $10 million already committed by PCF to research the African-American prostate cancer disparity and provide tests and treatments for better health equity.

With more teams bringing this issue to center court, life-saving information about risks and screening reached more than 800,000 people, including fans at All-Star weekend. Thanks to these 6 teams, men of all ethnicities were encouraged to know their risk and get appropriately screened.
Finding Prostate Cancer Earlier... and (Much) Earlier

A highly sensitive new prostate cancer scan: PSMA PET

In 2020, a highly sensitive new imaging scan for prostate cancer may be FDA-approved: PSMA PET. PSMA PET is more sensitive than all standard prostate cancer imaging options, including CT, bone scans, MRI, and $^{18}$F-fluciclovine (Axumin) PET.

PSMA PET scans will enable earlier detection of metastatic disease, which is particularly relevant in patients newly diagnosed with high-risk prostate cancer, and in patients who are experiencing a rising PSA after surgery or radiation. Clinicians are testing whether using PSMA PET to direct radiation therapy in patients who have recurrent disease in the pelvis, or just a few metastases, will improve outcomes.

The PSMA PET imaging agent currently under FDA review is $^{68}$Ga-PSMA-11, based on studies led by PCF-funded investigators Dr. Thomas Hope at the University of California, San Francisco, and Dr. Johannes Czernin and Dr. Jeremie Calais at the University of California, Los Angeles. A second PSMA PET imaging agent, $^{18}$F-DCFPyL, which was developed under a PCF Pilot Award, will be considered by the FDA in 2021. Several other PSMA PET agents are in various stages of clinical development.
The first global Hagen Family Center of Excellence for prostate cancer theranostics

“Theranostics” – aka therapy + diagnostics, is a promising new precision medicine approach in which the same cancer protein is targeted for both cancer imaging and treatment. Ideally, the imaging is used to identify patients who will receive the treatment. In prostate cancer, PSMA is the most advanced example of this: PSMA PET imaging may soon be FDA-approved, and many PSMA-targeted treatments are being tested in clinical trials.

Enabled by a $5 million gift from the Hagen family, in 2019 PCF established the Australian Prostate Cancer Theranostics and Imaging Center of Excellence (ProsTIC) at the Peter MacCallum Cancer Centre in Melbourne, Australia. Led by Professor Michael Hofman, MBBS, this Centre will be a global leader in conducting clinical trials and cutting-edge research on new theranostic approaches in prostate cancer and in educating clinicians on the optimal use of these sophisticated new imaging agents and treatments in patients.
Over the last year, the Prostate Cancer Foundation (PCF) notably expanded our Center of Excellence (COE) Network in partnership with the Department of Veterans Affairs (VA) through the generosity of several philanthropic donors who are united in the goal of providing best-in-class prostate cancer care to veterans. Four new COEs have joined our dedicated network of centers executing the ambitious mission of delivering cutting-edge precision treatments to improve the lives of U.S. veterans with prostate cancer. With the addition of the new centers, PCF has established 10 COEs to date, collaborating in a network called Precision Oncology Program Cancer of the Prostate (POPCaP Network).

More than 15,000 men in the Veterans Health Administration (VHA) are newly diagnosed with prostate cancer each year. PCF is committed to funding the most promising research and improving prostate cancer care for veterans.
prostate cancer, and an estimated 500,000 veterans are battling prostate cancer in the VA.

The PCF has also dedicated funding to the research of numerous VA physician scientists. The platform curated by the PCF and VA is being used to build centers of excellence for several other forms of cancer and life-threatening illness including COVID-19.

“We are proud to be in partnership with the VA to deliver exceptional treatment options to our Nation’s veterans and we want each and every one to know that these Centers of Excellence exist and how to access them,” said Jonathan W. Simons, MD, PCF’s president and CEO. “No veteran should be left behind when a medical breakthrough comes to the clinic. It is our duty to ensure every veteran receives the very best care, and access to new precision treatments.”

June 10, 2019 – Fellow University of Pennsylvania alumni and philanthropists Marc and Mindy Utay (Utay Family Foundation) and PCF emeritus board member Andy J. Astrachan (AJA Charitable Foundation) join medical oncologists, molecular biologists, clinical geneticists, and early-career scientists supported through their visionary philanthropic support for the Jonathan and Plum Simons Precision Oncology Center of Excellence at the Corporal Michael J. Crescenz VA Medical Center (Photo by Philadelphia VA Medical Center)
Leveraging Relationships and Passion into New Research Dollars

2019 Special Events

PCF’s special events continue to be a platform for some of our most successful fundraising efforts. Without having national affiliate chapters, PCF has established events in key cities throughout each year to meet and share our critical work. These events provide unique opportunities to introduce the work of PCF, interact with our leadership team, meet our PCF-funded researchers, and raise awareness within those communities. The events have been instrumental in fostering new relationships and deepening existing ones to fund our most innovative life-extending research programs.

For over 20 years, PCF’s pro-am tennis tournaments have seen hundreds of professional and amateur tennis players take to the courts and brought thousands of weekend attendees to join in our fight against prostate cancer. 2019 was another stellar year that provided exciting and unique experiences for players and guests alike. In February, we kicked off the season in Palm Beach, Florida at The Breakers, followed by the Indian Wells, California tournament played on site during the BNP Paribas Open at the Indian Wells Tennis Garden in March. The Hamptons, New York tournament rounded out the season in August. The Hamptons weekend has continued to expand and is now recognized as one of the top 5 annual events in the Hamptons. It now includes tennis on private courts, a series of robust dialogues on major topics of interest, and culminates with a gala party at the Parrish Art Museum. This year included a special performance by award-winning artist, Bryan Adams.

The tennis tournaments in 2019 raised over $4.6 million, including $2 million in special PCF awards.

The year concluded with our annual celebratory New York Dinner at the legendary restaurant DANIEL. With a specially-prepared menu by chef Daniel Boulud and limited to 130 people, the dinner is a highly anticipated event that provides a more intimate setting to highlight the accomplishments of our Global Research Enterprise. This year included a special performance by master mentalist, Lior Suchard, and concluded with an electrifying performance from Grammy and Oscar award-winning artist, Jamie Foxx, that brought everyone to their feet. With a clear focus on supporting new scientific programs, the evening brought in more than $4.2 million, including $1,125,000 for 5 new PCF Young Investigator Awards and $1,850,000 for 4 new PCF Team Science Challenge Awards.
Eric Davidson, a 20-year veteran of the PCF tennis program, gets into the swing of things at the Hamptons tournament.

Multi-award-winning artist Bryan Adams surprised guests with a special performance at the Hamptons Gala Dinner.

2018 Nobel Prize recipient and early PCF-supported researcher Dr. Jim Allison joins PCF Chairman Mike Milken on stage in the Hamptons.

Generous donors at PCF’s 2019 New York Dinner at DANIEL.

Master mentalist Lior Suchard delivers the right message at the DANIEL Dinner.

Multi-talented entertainer Jamie Foxx, singer-actress Katherine McPhee, Chairman Mike Milken, and David Foster join for a very memorable evening at the DANIEL Dinner.
Since 2007, the Movember Foundation has been a definitive leader in accelerating prostate cancer research. Through its annual mustache- and awareness-growing fundraising activities and other key events, the organization has donated over $58 million to the Prostate Cancer Foundation in support of 74 research awards in the U.S., Canada, and Great Britain. We are honored to continue the work of this incredible partnership which has led to life-p prolonging and life-improving oncology developments for patients in need.

Thanks to Movember funding:

- Two new precision medicine treatments have been discovered for patients who have DNA repair gene mutations in their tumor, and these treatments will likely soon be approved by the FDA.
- The discovery that inherited DNA repair gene mutations increase risk for prostate, breast, ovarian, and other cancers has led to precision genetic counseling for family members of men with prostate cancer.
- More than 70 clinical trials testing new prostate cancer treatments and imaging technologies have been initiated.
- A more sensitive new imaging technology, PSMA-PET, has been developed for visualizing prostate cancer recurrences earlier.
- Many new drugs have entered the R+D pipeline for treatment-resistant prostate cancer.
- Biomarkers, including AR-V7, have been discovered that help doctors to choose the most appropriate treatments for patients.
- Blood tests are being developed to analyze tumor mutations so that patients can avoid invasive biopsies of metastatic disease.

Movember Foundation Global Director of Biomedical Research Programs, Mark Buzza (fifth from left), and Executive Director of Programs, Paul Villanti (far right), pose with recipients of the 2019 Movember Foundation-PCF Team Science Challenge Awards at PCF’s 26th Annual Scientific Retreat in Carlsbad, CA.

PCF is profoundly grateful to Movember for this life-saving partnership.
When the Entertainment and Sports worlds unite around a great cause like the Prostate Cancer Foundation, it translates into greater fundraising for our research programs. Such is the case for a core group of donors supporting our efforts in honor of an icon in the entertainment world: Jerry Weintraub.

Jerry had a passion for all of humanity: in both life and in his films, he always found the goodness in our hearts to do the right thing. The Jerry Weintraub Celebrity Pro-Am Golf Tournament merges Hollywood and Professional Golf, with the people who knew and loved Jerry.

Hosted for the second time at the impeccable and exclusive Madison Club in La Quinta, CA, The Jerry II brought together some of Weintraub’s closest friends for a day of first-rate golf, fundraising, and good times. We extend special thanks to all of our sponsors, including Casamigos, Indigo Auto Group, and the Weintraub Family Foundation, as well as our friends and donor-partners: CBS All Access, Garmany Golf, Under Armour, and Ritmo Mundo, who produced our beautiful limited-edition custom watches for our golfers. In total, the event raised more than half a million dollars for PCF research and partnering charities.
During PCF’s 2019 Home Run Challenge Tour, the Dickson Family joined PCF Founder and Chairman Mike Milken for the PCF-Seattle Mariners Home Run Challenge game. To honor the memory of their beloved daughter, Andy Dickson’s employer, the Odyssey Group, partnered with PCF to establish the Kelsey Dickson Team Science Courage Research Award at the Fred Hutchison Cancer Center. Project leads Drs. Peter Nelson and Paul Nghiem are leading a study encompassing the overlap of Merkle Cell Carcinoma and small cell prostate cancer, advancing us all that much closer to a cure across multiple forms of cancer.
PCF Team Up for a Cure!

Baseball legend Steve Garvey joined the HRC Crew to promote prostate cancer awareness in San Diego.

Dennis and Janet Barnett continued to support PCF through the RNDC Sponsorship of HRC.
Sheffler Strong

When Pat Sheffler’s son needed to sell some more insurance to hit his bonus, Pat did what any good dad would: he bought more insurance from him. Before Brandon Sheffler could issue the new policy, his dad needed to undergo a routine physical; no problem, because Pat Sheffler, at age 53, was a multi-sport athlete – the kind of guy who runs marathons AND plays basketball 2 hours per day.

But the life insurance company called Pat with some concerning news – his PSA was 37. Brandon had already done some research and was ready with, “Don’t worry, Dad, it’s probably just a false positive.” Not so. Pat was diagnosed with Stage 3 prostate cancer.

“The biggest thing in my entire world is my family,” says Pat, “Very first thing I thought was, ‘My poor son.’ Your mind goes a million directions. After I calmed down, I remember thinking, ‘I am not missing my daughter’s graduation, no matter what.’”

Pat had stage 3 prostate cancer. In stages 1 or 2, PSA has started to rise, but the cancerous cells are confined to the prostate. In stage 4, the prostate cancer cells have traveled to other parts of the body, most commonly lymph nodes and bones. But in stage 3, the tumor has often started to bulge outside the prostate without (yet) any evidence of distant metastasis. 50%-80% of men who undergo surgery for stage 3 prostate cancer see their PSA rise again within 10 years.

Pat, 53 at the time of diagnosis, did his own extensive research on treatment, going as far as UCLA, USC, and the Mayo Clinic, only to determine that the best doctor to do his surgery was urologist Dr. Christopher Kane, right in his own backyard at UCSD. Furthermore, as luck would have it, there was a PCF-funded clinical trial, looking for high-risk patients with just his profile.

The trial, led at UCSD by PCF-researcher Dr. Rana McKay, in collaboration with Dana-Farber Cancer Institute, grew out of a 2014 PCF Challenge Award with study Principal Investigator Dr. Mary Ellen Taplin. It asks the question: “Can we cure more patients if we apply more potent hormonal therapies at the early stages of disease?”

“Before I even had the surgery, they put me on prednisone, Lupron, apalutamide and abiraterone.” Because Pat had a hormone-sensitive prostate cancer, the drugs he was on were designed to decrease androgens and block their activity. “I got tested every month before surgery and watched my PSA numbers drop – 34, 27, 21, 10, 4, 2, 0.2.” After surgery, Pat participated in the second part of the trial to test whether another year of hormone therapy would improve outcomes.

Pat had the surgery on November 5, 2018. The day before, he walked 5 miles with a friend who had been diagnosed with breast cancer at a similar time as he was diagnosed with prostate cancer. “She kept saying, ‘Why are you here, you have surgery tomorrow?’ and I kept saying, ‘I’m here because I don’t have surgery until tomorrow.’”
Pat has done 7 marathons and multiple Spartan-type races (some with his whole family). He’s played in the same community softball league for 40 years – in the 80s, with his dad, and now with his sons. He typically plays basketball 2 hours a day. He’s in about as good shape as you can be for a guy who’s 55.

“When I had the surgery, the doctor made a point of telling me how healthy I am on the inside. I played basketball before and after treatment – 13 hours a week, never missed a week. I eat whole foods and I’m a super positive person, no matter what. I think that matters. Life is what you make of it. My family never got depressed, because I never got depressed. Positive vibes is my thing.”

A few months after his diagnosis, Pat showed up to a softball game... only to find his son Brandon in a t-shirt that said “Positive Vibes” on the front and “Sheffler Strong” on the back. Then his other son, Tristen, showed up with the same shirt on. “I want one, why didn’t you get me one?” Pat said. And then his mom showed up with one. And his wife. And his friends and his nephew and another 20 people showed up with the same shirt. As Pat tells it, “I wear my heart on my sleeve, so it impacted me in a big way. Later after practice, we went to a local pizza place. ‘Why don’t you open Facebook?’ my daughter Ashlen said.” There, Pat found that his wife and daughter had orchestrated a secret Facebook group, where 100s of people around the world had all taken pictures of themselves in the same shirt.

The clinical trial and positive vibes finally paid off. A year after surgery, Pat went off the drug protocol. Two months later and still off the trial meds, his PSA was undetectable. Furthermore, his testosterone was rising back to normal. “It is a highlight of my profession,” says Dr. McKay, “This is how we get the next best therapies out there for patients. These are the moments and breakthroughs we look for. I always say, Remission + Time = Cure. My hope for Pat is that he’s cured – that he can go on just being an amazing dad, husband, and advocate for prostate cancer awareness.”

“What I take from this, from a selfish perspective, is that I’m proud that my life leading up to this was authentic. I’ve always been a positive, outgoing, happy person and that’s the truth. You would never know I was diagnosed with anything. We manifest our own health by positive energy, and a positive mindset is a big part of that.”

Pat Sheffler, surrounded by friends, family, and Positive Vibes
For the fourth year in a row, at the 2019 PCF Scientific Retreat, PCF acknowledged the amazing contributions that women have made in the field of science and medicine, specifically in prostate cancer research with the Annual PCF Women in Science Forum.

Before PCF began to encourage prostate cancer researchers by funding their early careers, the numbers of women in the field were few. Through our Young Investigator Awards and Team Science Challenge Awards programs, PCF has helped to increase the number of women who are building a long-term career in prostate cancer research.

Dr. Andrea Miyahira – who has been instrumental in leading the program – described the benefits. “It has been so rewarding to be a part of this amazing group of scientists, clinicians, and leaders in the field. As PCF’s Director of Global Research, I have seen many young women investigators grow their skills through mentorship over the years.”

In 2019, in recognition of career issues unique to women, 4 female PCF-funded investigators, Drs. Karen Knudsen, PhD (Thomas Jefferson University), Lorelei Mucci, ScD (Harvard School of Public Health), Himisha Beltran, MD (Weill Cornell Medicine), and Amina Zoubeidi, MSc, PhD, hosted the PCF Women in Science Forum, to which all female (and any interested male) attendees are invited to attend. The goals of the Forum are to create a network of PCF-funded women scientists, to team-build through discussion and social events, to ensure a strong pipeline of female prostate cancer researchers and clinicians, and to identify opportunities for further training, mentoring, and synergy of a stellar network of female prostate cancer researchers and clinicians.
PCF Catalyzes the Development of a Polygenic Test for African American Men at Highest Risk

Studies of cancer in twins have revealed that 57% of all prostate cancer runs in families; one might say that this makes prostate cancer the most “family inherited” form of human cancer. For the last 20 years, the Prostate Cancer Foundation has been funding the detective work to figure out which single genes – out of 22,000 in the human genome – might be responsible for the most aggressive prostate cancers (for example, the BRCA1 and BRCA2 genes). Now, PCF-funded researcher Chris Haiman has made a significant finding, discovering that often it is not a single gene, but rather dangerous combinations of genes, that together severely increase lifetime risk for prostate cancer and run in families.

Here’s another way to think about this fascinating result. There are 100s of genes related to prostate cancer that you may have inherited from your parents. We now know there are several combinations of genes – think of it like a hand of cards you are dealt when you are born – that can confer significantly higher risk for aggressive disease. Haiman and his global research team also discovered that African American men are more likely to have been dealt a particularly bad hand: some of the worst combinations of genes for prostate cancer risk are unique to men of West African descent.

PCF has also spent many years trying to unravel the complexities of health disparity in prostate cancer for African American men, who are 76% more likely to be diagnosed and more than twice as likely to die from the disease. Using a comprehensive analysis of all the genetic risk data around prostate cancer for men of different ethnicities, including those of African descent, Haiman hopes to be able to create a test to assess a man’s lifetime risk of developing prostate cancer. This test has great potential, allowing doctors to identify men who may have up to 4 times higher risk of getting prostate cancer than the average guy; if we can get them tested and tracked earlier, we can save lives.

Because prostate cancer is 99% treatable if detected early, this “precision screening” test could be a game-changer for men’s health, as well as a key factor in reducing the overall disparity in death rate for men of African descent. More R+D is needed to optimize this innovative new test. As a next step, Haiman and team will make sure that cutoffs for risk groups are as accurate as possible, in the same way that the output of your cholesterol test places you in a high, medium, or low risk category for cardiovascular disease.
Supporting Cures

There are millions of men currently living with prostate cancer. To support the urgent need for better treatments and cures, the Prostate Cancer Foundation offers various options for becoming involved and supporting crucial research.

Donations
Please mail your check to:
Prostate Cancer Foundation
1250 Fourth Street
Santa Monica, CA 90401
To make an online contribution, please visit our website www.pcf.org

Blue Ribbon Society
▶ Join our elite group of loyal supporters devoted to fostering breakthrough science with a monthly recurring contribution

Memorial or Tribute Gifts
▶ Honor the memory of a loved one or celebrate the accomplishments of a friend or family member by helping others with a tribute gift
▶ If desired, PCF can also set up a special webpage to honor your loved one and collect donations

Matching Gifts
▶ If your company offers an Employee Matching Gifts program, you can make your hard-earned dollars go twice as far with a matching gift to PCF

Other Gift Suggestions
▶ Gifts of stock
▶ Support PCF in your estate planning
▶ Name PCF as a beneficiary of your IRA or life insurance policy
▶ Federal employees and retirees participating in the Combined Federal Campaign (CFC) can designate PCF as a beneficiary

For more information, visit: www.pcf.org/donate

PCF Research Awards
PCF advances its research priorities through three competitive award types:

Team Science Challenge Awards
($1,000,000 and above for 2- to 5-year programs)
Team Science Challenge Awards make large investments in multiyear projects that have a high potential for delivering new treatments and diagnostics.

Creativity Awards
($300,000 for 2-year programs)
Creativity Awards support the development of high-risk, high-reward ideas from established senior scientists.

Young Investigator Awards
($225,000 for 3-year career investment)
The Young Investigator Awards offer early-career and project support for the ideas of exceptional investigators (generally 35 years old and younger), who are committing their lives to the field of prostate cancer. Their institutions match the award dollar-for-dollar.

PCF-VA Center of Excellence Awards
In 2016, the PCF committed to invest $50 million over 5 years to advance precision medicine for America’s veterans. Together, PCF and the U.S. Veterans Administration are building a network of Precision Oncology Centers of Excellence focused on expanding access to genomic sequencing and innovative clinical research.
2019 Donor Roll

The support of our generous donors makes all that we do at PCF possible. This honor roll acknowledges actual gifts of $1,000 or more, exclusive of pledges, made to PCF during calendar year 2019. We thank you, our friends and supporters, for your continued commitment to PCF’s mission.

$1,000,000-$4,999,999
Stein Erik Hagen Almennnyttige Stiftelse
Janssen Research and Development, LLC
The John and Daria Barry Foundation
The Michael and Lori Milken Family Foundation
Movember Foundation
Odyssey Group Foundation
Ruvo Family Foundation
Lawrence R. Souza Revocable Living Trust

Mr. Anthony D. Minella and Mrs. Sage Minella
Mizel Family Foundations
Mr. Thomas S. Smith and Ms. Caroline Fitzgibbons
Thomas H. Lee and Ann Tenenbaum
Mr. Igor Tulchinsky
Mr. Larry J. Winget
Yurman Family Foundation, Inc.

$100,000-$149,999
Joseph and Annette Allen
AstraZeneca
Authentic Brands Group, LLC
Aven Foundation
Bill and Ann Bresnan Foundation, Inc.
Bristol-Myers Squibb Company
The Cleveland Clinic Foundation
Collier Capital
Mr. Paul Coulson
Neil and Sandra DeFeo Family Foundation
Mr. Louis Dorfman
Eldridge Business Services, LLC
Fuego Box LLC
Graziano Wellness Foundation
Michelle and Joseph Jacobs
Jordan Industries, Inc.
Eric A. Klein, M.D.
Mr. Gary A. Lieberman
M. C. Dean, Inc.
Major League Baseball Charities, Inc.
Meck and Co., Inc.
Minnesota Twins
Paulson Family Foundation
Republic National Distributing Company, LLC
Cliff and Debbie Robbins and The Robbins Family Foundation
Ms. Alice Rogoff and Mr. David M. Rubenstein
Mark and Rosalind Shenkman
Mr. Scott Simon and Mrs. Hillary Simon
Sun Capital Partners, Inc.
The Wagner Family Foundation
Mr. Andrew S. Weinberg

$50,000-$99,999
Dr. Elliot Abramowitz
Advanced Accelerator Applications
Anonymous (3)
Astellas Pharma Global Development, Inc.
Baratta Family Fund
Douglas and Joanne Berry Charitable Fund

Greg and Anna Brown Family Fund
Mr. Mike Burkland and Mrs. Kathy Burkland
Arthur and Eva Byrnes
Casamigos Tequila LLC
Howard Cox
Mr. Tim Connors
CRIS Foundation
Daiichi Sankyo, Inc.
Mr. Michael DeAddio
Dendreon Corporation
Derrick’s Day for Prostate Cancer Awareness
Donnini-Rudolph Family Foundation
The Eustace Foundation Trust
Eugene and Sallyann Fama
Mr. Thomas M. Finke and Mrs. Heather Finke
Keith Frankel
Julie and Martin Franklin Family Foundation
Peter and Laurie Grauer
Clay and Lynn Hamlin
Mr. Timothy A. Hanson and Mrs. Alida J. Hanson
William B. Harrison Foundation
HLT Prostate Cancer Fund
Kissick Family Foundation
Kovler Family Foundation
The Laughlin Aldisert Family Fund
Dalia and Larry Leeds/The Leeds Family Foundation
The Frances And Craig Lindner Foundation
The Maguire Foundation
Charles N. Mathewson Foundation
Model’s Inc.
The Donald R. Mullen Family Foundation, Inc.
The Nerney Foundation
Progenics Pharmaceuticals, Inc.
Ressler/Gertz Family Foundation
Brian and Patricia Reynolds
Michael J. Rinaldi Jr. Revocable Trust
Riverview Flats Pty, Ltd
Daryl and Steven Roth Foundation
The San Francisco Foundation
Mr. Leonard Sands
Ms. Lucy Shostak
The Robert and Jane Toll Foundation
The Weintraub Family Foundation
Wild Dunes Men’s Golf Association
Wycliffe Country Club Men’s Golf Association
Zisk Family Foundation

$25,000-$49,999
Anonymous
The Elia, Genevieve and Georgina Atol Charitable Trust
The Cecile and Fred Bartman Foundation
Candice Beaufont
Arthur Becker and Vera Wang
The Sybiel B. Berkman Foundation
Jay and Alison Bernstein
Mr. and Mrs. Seth Bernstein
Mr. Miles Boldrick
Anthony and Jamie Carr
Johnny Carson Foundation
Dick and Lisa Cashin
CBS Interactive US
Celgene Corporation
Chicago White Sox
Mr. Joe Capriano
Robert D. Collins Fund
Mr. Jon Corn and Mrs. Dawna Corn
John R. and Kiendi Dauphinton Foundation
Mr. and Mrs. Eric K. Davidson
ECOR1 Capital, LLC
Faith, Love, Hope, Win Foundation
Ralph and Cynthia Finerman
Flanagan Family Gifting Account
Friedman-French Foundation, Inc.
Fuhrman Family Foundation
Genentech, Inc.
Mr. Gerald Gibian
GoldenTree Asset Management
Mr. Jeff Greene and Mrs. Mei Sze Greene
John A. Griffin
Johnson & Johnson Services, Inc.
Mr. and Mrs. Steven B. Klinsky
Stephanie and Ron Kramer
Lateral Investment Management, LLC
Ms. Jane A. Lauder
Mr. Paz Littman
John and Linda MacDonald Foundation
Mr. and Mrs. Donald B. Marron
Medical Research Charities
Jerome Meislin
Mr. Michael A. Mendelson
Ted and Dani Virtue
MJR Foundation
Mr. Terry R. Montesi and Mrs. Allison Montesi
The Moreno Family Foundation
Mr. Mark E. Nicol
Mr. Gerald E. O’Shaughnessy
Paluszek Family Foundation, Inc.
Power Design, Inc.
R.S. Evans Foundation
Rance King Properties, Inc
Marc J. and Carolyn Rowan

$50,000-$99,999
Atlanta Hawks Foundation, Inc.
Reina and Emilio Bassini
Dr. Michael M. Berns and Tricia Berns
Susan and Jim Blair
Todd Boehly
Clovis Oncology, Inc.
The Durden Foundation, Inc. / Mr. Michael Durden / Mrs. Earl Durden
David and Judith Fleischer
Shmuel Meitar

$250,000-$499,999
Anonymous
Bayer HealthCare Pharmaceuticals, Inc.
Robert and Cynthia Citrone
Facebook, Inc.
Genzyme Corporation
J. C. Kennedy Foundation, Inc.
Herb and Natalie Kohler
Fred B. Luddy Family Foundation
Heritage Medical Research Institute
Sun Pharmaceuticals Industries
Teach A Man To Fish Foundation

$500,000-$999,999
AJA Charitable Fund
Anonymous
The John Black Charitable Foundation
Brewers Community Foundation, Inc.
Credit Suisse Securities (USA) LLC
Edelman Family Foundation
Edward P. Evans Foundation
The David Geffen Foundation
Heritage Medical Research Institute
Sun Pharmaceuticals Industries
Teach A Man To Fish Foundation

$150,000-$249,999
Atlanta Hawks Foundation, Inc.
Reina and Emilio Bassini
Dr. Michael M. Berns and Tricia Berns
Susan and Jim Blair
Todd Boehly
Clovis Oncology, Inc.
The Durden Foundation, Inc. / Mr. Michael Durden / Mrs. Earl Durden
David and Judith Fleischer
Shmuel Meitar

$25,000-$49,999
Anonymous
The Elia, Genevieve and Georgina Atol Charitable Trust
The Cecile and Fred Bartman Foundation
Candice Beaufont
Arthur Becker and Vera Wang
The Sybiel B. Berkman Foundation
Jay and Alison Bernstein
Mr. and Mrs. Seth Bernstein
Mr. Miles Boldrick
Anthony and Jamie Carr
Johnny Carson Foundation
Dick and Lisa Cashin
CBS Interactive US
Celgene Corporation
Chicago White Sox
Mr. Joe Capriano
Robert D. Collins Fund
Mr. Jon Corn and Mrs. Dawna Corn
John R. and Kiendi Dauphinton Foundation
Mr. and Mrs. Eric K. Davidson
ECOR1 Capital, LLC
Faith, Love, Hope, Win Foundation
Ralph and Cynthia Finerman
Flanagan Family Gifting Account
Friedman-French Foundation, Inc.
Fuhrman Family Foundation
Genentech, Inc.
Mr. Gerald Gibian
GoldenTree Asset Management
Mr. Jeff Greene and Mrs. Mei Sze Greene
John A. Griffin
Johnson & Johnson Services, Inc.
Mr. and Mrs. Steven B. Klinsky
Stephanie and Ron Kramer
Lateral Investment Management, LLC
Ms. Jane A. Lauder
Mr. Paz Littman
John and Linda MacDonald Foundation
Mr. and Mrs. Donald B. Marron
Medical Research Charities
Jerome Meislin
Mr. Michael A. Mendelson
Ted and Dani Virtue
MJR Foundation
Mr. Terry R. Montesi and Mrs. Allison Montesi
The Moreno Family Foundation
Mr. Mark E. Nicol
Mr. Gerald E. O’Shaughnessy
Paluszek Family Foundation, Inc.
Power Design, Inc.
R.S. Evans Foundation
Rance King Properties, Inc
Marc J. and Carolyn Rowan
Mr. Richard Stone and Mrs. Lesley Stone
Wallack Family Foundation

$10,000-$14,999

Acquavella Family Foundation
Anonymous (3)
Eric Aroesty
Assaf Family Trust
Mr. Duncan Bagshaw and Mrs. Lisa Bagshaw
Barclays
Ron and Judy Baron
Mr. Keith Bertolino
BNP Paribas USA, Inc.
Mr. and Mrs. David C. Brown, Jr.
Calamos Advisors, LLC
Gary Charlesworth
Charlesworth FLP
Ms. Joann Chasen
Courtney and David Corletto
Mr. Jack Curtin and Mrs. Beth Curtin
Mr. Gary S. Davis and Mrs. Ellen Davis
Mr. Alex Engemann
Andrew H. Feinman
Fuente Family Foundation, Inc.
Mr. Glenn Fuhrman
Mr. James Gary and Mrs. Sylvia Gary
Mr. Michael Gismondi
Mr. Greg Gliner
Mr. Justin Gmelich
Mr. R. Stephen Hannahs
Mr. Robert F. Hogan, Jr.
Eric D & Steven D Hovde Foundation
Clark,com
Mr. David B. Humphot and Mrs. Barbara W. Humphot
Hurwitz Family Foundation
JP Morgan Chase & Co.
Chris & Mary Ellen Kanoff Family Foundation
Mr. Bradley R. Krevoy
Devi Kupsammy
Mr. Carey F. Lathrop
Heyson C. Leach
The Lefkofsky Family Foundation
Mr. and Mrs. John Lucchesi
Suzi and Scott Lustgarten Family Foundation
Mr. Howard Lutnick and Mrs. Allison Lutnick
Mr. and Mrs. Robert J. Dunne III
Mr. Bret D’Vincent
Stephen Edelmann, Edelmann Family Foundation
Elisabeth Ventura and Stephen Eisenmann
Mr. Jonathan P. Evans
Dr. Jeffrey P. Feingold
Mr. and Mrs. George A. Mealey
Mr. Robert G. Fuller Jr.
Ms. Gayle Gaines
German Masonic Charitable Foundation
Ms. Olivia Miller
Mr. Gerald L. Parsky
Mr. Andrew Weinberg
Mr. Robert S. Kricheff and Mrs. Daphne A. Bowe
Mr. Michael Lichtenberg
Mr. Edward L. Newburger
Mr. and Mrs. Donald A. McMullen, Jr.
Mr. and Mrs. William L. Price
Mr. and Mrs. Paul Madura
Mr. and Mrs. Daniel Weingast
Mr. and Mrs. Ralph Eads, III
Mr. and Mrs. Jeffrey Schottenstein
Mr. and Mrs. Dave Perron
Mr. and Mrs. George A. Mealey
Mr. Robert Perron
The Powers Family Foundation
Estate of Michael Eugene Preston
Roman Health Ventures Inc.
San Diego Golf Course
Superintendents Association
Mr. and Mrs. Jeffrey Schottenstein
William and Valerie Schwartz Family Foundation
Mr. Michael H. Scott
Shutterfly, Inc
David E. and Jacqueline S. Simon Charitable Foundation
Herbert Simon Family Fund
Skelton Family Fund
Gary Stonebunner
Mr. Peter Strelow
The Tuchman Family Foundation
UBS AG
Mr. Robin Ventura
Mr. Ron White
Art Winkleblack

$5,000-$9,999

Joseph P. Adams, Jr.
Mr. Lee Adrear
Anonymous (8)
Mrs. Shari L. Aronson
Paul Baranay
Roger Barnett
Mr. William P. Becker and Mrs. Debbie Becker
Battle at Bella Vista
Bananza Casino
C.A.R.E (Cancer Alzheimers Research Event)
Canoe Brook Country Club
Jared Carney and Mrs. Deidre Wallace Carney
Mr. and Mrs. Richard Chadakoff
Mr. Howard Chai
Allen and Jill Chozen
Mr. David R. Chubon
Dauber Foundation Fund
Mr. A.W. Dieffenbach, Jr.
Mr. and Mrs. Robert J. Dunne III
Mr. Bret D’Vincent
Stephen Edelmann, Edelmann Family Foundation
Elisabeth Ventura and Stephen Eisenmann
Mr. Jonathan P. Evans
Dr. Jeffrey P. Feingold
Mr. and Mrs. George A. Mealey
Mr. Robert G. Fuller Jr.
Ms. Gayle Gaines
German Masonic Charitable Foundation
Mr. Stephen A. Gillin
Mr. Jonathan Goldstein
Mr. Julian Gordon
Mr. Joseph G. Greenberg and Mrs. Claire L. Greenberg
Mr. Mark S. Henderson
Douglas J. Hertz Family Foundation
Mr. and Mrs. Raymond Hwang
The Hwang Foundation
Ms. Julie C. Jaeger
Ms. Sheryl Kaye
Mr. Vernon Keist
Kelsey Family Charitable Fund
Memorial Sloan Kettering Cancer Center
Mr. Casey Kirkman
Mr. Thomas P. Knight
Strengthen, Gratitude, & Heroes
Kathleen and Kirk Knous
Stacey and Larry Kohl
Mr. Robert S. Kricheff and Mrs. Daphne A. Bowe
Mr. Philip Larman
Dr. Edward Loftspring
Mr. George Liao
Dr. Edward Loftspring
Mr. and Mrs. Harry Lee
Lords Valley Country Club
Mr. John Lykouretzos and Mrs. Joella Lykouretzos
Mr. and Mrs. Paul Madura
Manowitz and Drillings Family Foundation
Mr. Steve Mark
Mr. and Mrs. Michael W. Urbut
Mr. and Mrs. Robert Lee
Mr. and Mrs. Douglas P. Sadow
Mr. Michael L. Price
Mr. and Mrs. William L. Price
Mr. and Mrs. Ross C. Shriver
Mr. and Mrs. Andrew C. von Eschenbach
Mr. and Mrs. Daniel Weingast
Mr. and Mrs. Michael W. Urbat
Mr. and Mrs. Robert Lee
Mr. and Mrs. Andrew C. von Eschenbach
Mr. and Mrs. Michael W. Urbat
Mr. and Mrs. Andrew C. von Eschenbach
Mr. and Mrs. Andrew C. von Eschenbach
Mr. Robert K. Cohen
Ms. Christine Cole
Mr. James H. Cole
Ms. Jennifer R. Cole
William S. Comanor, PhD
Mr. and Mrs. Kurt A. Conti
Mr. Sean W. Coogan
Mr. Clay Cook
Mr. Joe Cover
Mr. Jeffrey Cox
Dr. and Mrs. Ross L. Crist
Mrs. Doris Crouch
Ms. Sandy Fairbarg
Mr. Peter Evensen and Mrs. Susan Evans
Insulation Company
Mr. and Mrs. Edward R. Evans
Englewood Cliffs Police
Mr. Albert L. Engel and Mrs. Jane M. Engel
Mr. Bob Emmelkamp
El Conquistador Mortgage
Mr. Pete Eischen
Mr. and Mrs. James W. Eggenberger
Mr. and Mrs. Grant Edwards
Edrington
Mr. William Duttlinger
Mr. James W. Durst
Mr. Peter J. Durfee
Mr. Sean Durbin
Michael Dunitz Crisis Foundation
Mr. Joseph F. Duerr
Mr. Brian Duchinsky
Ms. Tina Driscoll
Mr. and Mrs. William E. Dreyer
Ms. Marian R. Foldberg
Mr. Peter Foster
Mr. Jack Foxworth
Mr. Charles Frankel
Larson Freitag Charitable Giving
Dr. and Mrs. Mark H. Fritzke
Mr. and Mrs. William Frumkin
Mr. William C. Fuller, Jr.
Mr. Jacob Gantz and Mrs. Leigh Gantz
Mrs. Nancy H. Gardner
Mr. Joshua Gartner
Mr. and Mrs. J. Donald Garvey
Mr. Robin Gates and Ms. Jan Fulwiler
Mr. Anthony Geisler
Ms. Sheila Germaine
Mr. and Mrs. Donald A. Gill
Mr. Pier Giorgetti
Mr. James Gizzonio
Mr. and Mrs. David Goetz
Mr. Raj Gohill
Ms. Susanne Gold
Mr. Myles Goldstein
Dr. Ronald Goldstein
Mr. Michael L. Gollobin and Mrs. Laura S. Gollobin
Ellen M. Golub Charitable Foundation
Mr. Gary Gordon
Mr. James Gordon
John P. Gould and Kathleen A. Carpenter
Mr. and Mrs. Jonathan P. Goulding
Mr. Tsahi Gozani
Mr. Bill Green
Mr. William L. Gregory
Mr. Brendan Griffth and Mrs. Lynn Griffth
Mr. Charles Grimes
Mr. Thomas Groening and Mrs. Elizabeth Groening
Mr. Paul Guagliardo
Mr. Wayne E. Habeck
Thomas H. Hagadone and Pamela J. Miller
Mr. Dana Hagen
Mr. Robert S. Hagge Jr
Mr. and Mrs. Raymond A. Haines
Mr. Rex Hamilton and Mrs. Joan Hamilton
Mrs. Douglas S. Hansen
Ms. Julie A. Hansen
Mr. Nathaniel Hansford and Mrs. Frances Hanford
Mr. and Mrs. Harold E. Rickards
Mr. Craig Haskins
Mr. Andrew Hatter
Jerry and Marilyn Hayden
HDR
Mr. and Mrs. H. Peyton Henderson
Mr. and Mrs. David P. Henninger
Hermosa Beach POA
Mr. and Mrs. Henry G. Herzog
Mr. Robert F. Hirsch
Mr. Don Hirth
Mr. Douglas Hobbs
The Patsy and Michael Hochman Charitable Foundation
Mr. William E. Honey
The Jacobs Institute and the State University of New York Buffalo
Mr. and Mrs. Larry Horn
Ms. Aviva Carmy and Mr. Harry Horowitz
Mr. William Hudnell
Mr. and Mrs. Jack Hudspeth
Mr. Kenneth Hukari
Mr. Robert J. Hunter
Dr. Ian Jones
IFL, LLC
Mr. Rod Jack
Jacobs Family Foundation
Mr. Roland Jarmusch
Mr. Adam Jasperson
Mr. Jefferie Kane
Mr. James Jenkins
Mr. and Mrs. Daryl J. Jepson
Mr. and Mrs. John Jester
Mr. Michael Jones and Mrs. Dorothy P. Jones
Mr. Thomas G. Kamasik and Mrs. Ann L. Kamasky
Mr. Barry Kamel and Mrs. Debra Kamel
Ms. Harisen Kardon
Mr. Adam Katz
Mr. Ira Katz
Mr. Mitchel Katz and Mrs. Meredith Katz
Mr. Neil Katz
Keeler Motor Car Company Charitable Foundation
Mr. Kenneth A. Jones
Mr. Joseph A. Kiat and Mrs. Penny Kiat
Mr. and Mrs. John P. Kiley
Mr. Christopher Kleiman
Mr. Lloyd Klein
James W. Klein
Harold and Shirley Kobliner
Mr. Matthew Koren
Mr. Richard S. Kramer
Mr. Wilson Kriegel
Dottie and Tom Krull
KSB Dental
Mr. Robert Kuepper
Mr. and Mrs. Frank Kulze
Mr. James Kuykendall
La Verne Police Officer’s Association
LA-CO Industries, Inc.
Lakeland Bank
Mr. Patrick Lancaster
Joshua M. Lang, M.D.
Lucy and Paul Lange, M.D.
Leading Systems Technologies
Mrs. Susan L. Lebovitz-Edelman
Ms. Kay Ledyard
Ms. Suzanne Leeds
Mr. Mark Leffers and Mrs. Janine Leffers
Dr. Daniel Lehman
Mr. and Mrs. Richard H. Lester
Mr. George Levine
Ms. Pito Linn
Mr. Robert S. Linnell
Mr. Jack Loeb, Jr.
Mr. Kevin Lofton
Mr. Gabriel Loh and Mrs. Susan Loh
Mr. and Mrs. Gerald A. Long
Chris and Krista Loose
Douglas R. Lowe
Charles Lowrey and Susan Rodriguez
Mr. Victor Lucadamo
Mr. and Mrs. Christopher Luetzow
M & T Charitable Foundation
Gordon Maahs
Mr. Michael G. Mackay
Mr. Mike Mackay
Mr. Jeff MacLellan
Mr. Roderick MacLeod
Make My Donation, Inc.
Mr. Jacob Mandel
Ms. Sandra Mantine
Mr. William D. Marcum
Mr. Bernardo Mariano, Jr.
Marlborough Country Club Women’s Golf Association
Stanley and Pamela Maron
Mr. Douglas G. Martin
Mr. James Marzen
Mr. David Mason
Mr. Daniel May
Mr. Atwood R. McAndrew, Jr., Ms. Juliet McCarthy
Mr. Frank McClendon
McCown Family Foundation
Mr. Mark McCready
Mr. Brian J. McGuinn
The Mcllevey-Daugherty Family Foundation
Mr. Mark Mckinley
James and Ann McKinney
Laureston and Barbara McLeann
Mr. Patrick and Alicia McMahon
Mr. and Mrs. Harry McMillan/McMillan and Associates
Mr. Bryan McQuattie
Mr. and Mrs. Joseph M. Mego
Mr. Robert Mehm
Ms. Barbara J. Meislin
Mr. Jack Melnicki
Mr. Mark Mercer
Mr. and Mrs. Jack Meyers
Mr. Paul J. Milbury
Mr. Robert J. Milhiser and Mrs. Carol J. Milhiser
Ted and Donna Miller
Mr. Burckhard Mohr
Mr. Patrick Moore
Bill Morgan
Linda and Michael Morgan
Mr. Robert Moritz
Mr. George Mueller
Muller Family Foundation
Mr. Yegevnuri Muravchik
Mr. Michael Muzzy
PCF Community Fundraisers

Participants who raised $1,000 or more

- Andy Astrachan
- Aux Sable Liquid Products LP
- Julie Rose Dodson Baisinger
- Baker Botts, LLP
- Brandon Bourbon
- Catherina Brown and Styles of Steppin’ Seattle
- Ken J. Buck and Mrs. Cathleen A. Buck
- Marie Dorn and the Ghayal Family
- Don Ellenberger
- Fleetcor
- Dave Fleming and Craig Bell
- Gohill Orthodontics
- Dan Haase
- Kelly Hayes
- Hernando Firefighters Benevolent Relief Fund
- Tyler Holden
- Howard on Driving: Derric’s Day
- HOPE Motorcycle Rally
- Raymond Hwang and the Hwang Family
- Joseph, Penny and Colin Kiat
Blue Ribbon Golf Tournaments
Golf tournaments that raised $1,000 or more
10th Annual Pros4Care - Texas
12th Annual HLT Texas Shootout
13th Annual FLHW Golf Tournament
5th Annual 19th Hole Classic
8th Annual C.A.R.E. Golf Outing
8th Annual Jay Moody Memorial
8th Annual Sadie Hawkins GT
Annual Prostate Cancer Research Invitational
Battle at Addison Reserve
Battle at Bella Vista
Battle at Brookhills
Battle at Burlington & Rally for the Cure
Battle at Canoe Brook
Battle at Palm Beach
Battle at Pelican Pointe
Battle at Rarity Bay
Battle at the Meadow Club
DSB Invitational
El Conquistador Prostate Cancer Tournament
Friends of Dermot Brennan
Joseph DiNapoli, Sr. Memorial GT
Lehigh Valley MGA
Luetzow Charity Golf Outing
Opening Day Golf Tournament
Palm Aire Prostate Tournament
Save the Balls FORE PC
Sheffield Pharma for PC Research
Sweetwater Mens Cancer Tournament
University Park Member-Guest for PCF
Wild Dunes MGA Member/Guest
Willowbrook RCM Memorial
Wycliffe CC MGA

Blue Ribbon Society
Our community of monthly donors
Anonymous
Mr. Steve M. Abbott and Mrs. Diana M. Abbott
Mr. Steven Aberblatt
Mr. and Mrs. Hal Absher
Mr. Robert M. Agans
Mr. Larry Aiken
Mr. Mohamed Alhimmadi
Mr. Donald Allen
Mr. Dean Ambrose and Mrs. Dianne Ambrose
Mr. Paul N. Anderson
Mr. Paul Anderson
Mr. M. Douglas Archer and Mrs. Pat Archer
Ms. Christine Auerbach
Mr. Michael Bankert
Mr. Stephen Y. Barrow
Mr. Tom Barton
Mr. Mark Bass
Mr. Donald Beier
Mr. Percy B. Bell
Mr. Barry Berglund
Mr. Dennis E. Bernard
Mr. John P. Bernier and Mrs. Donna Bernier
Mr. Richard H. Bickerstaff
Mr. Michael Bigini
Mr. Michael Bivens
Mr. Robert Blum
Mr. Steve Borowski
Mr. Raymond Boyce
Mr. Laurence Brady
Mr. Jerald Brannon
Mr. and Mrs. Gerald Brenke
Mr. Robert T. Brew, Jr.
Ms. Dakota Briggs
Mr. Ramon Bristol Castillion
Mr. John Brophy
Ms. Amanda Brown
Mr. Scott C. Brown
Mr. Stuart P. Brown and Mrs. Jeanine Brown
Mr. George Brucks
Mr. Henry L. Burks and Mrs. Diana Burks
Ms. Patricia Burton
Mr. Joe Butler
Mr. Roger Byford
Mr. Danny A. Byler and Mrs. Rose Byler
Mr. Sean Caillias
Mrs. Amy Caimano
Mr. Ernest Campos
Mr. Frank V. Cardone and Mrs. Adrienne Cardone
Mr. Steve Carney
Mr. David P. Caroella
Mr. William Carr and Mrs. Jean Carr
Mr. David Cassino
Mr. Howard Chai
Mr. Gary Chamblee
Mr. Lou Chapman
Mr. Steven Chapman
Mr. Scott Chaudoir and Mrs. Lisa Chaudoir
Mr. Arthur P. Chimes
Mr. Jeff Chinn
Mr. Graham Church
Mr. Matthew Cifichiello
Mr. James H. Cole
Ms. Tama Coleman
Mr. Cory Compton and Mrs. Jacqueline Compton
Mr. Michael Conway
Mr. Clay Cook
Mr. and Mrs. Steven Cooper
Mr. and Mrs. Stephen Crones
Mr. Ted Costa
Mr. Michael Costin
Mr. Craig J. Couture
Mr. Bruce Cox
Mr. Charles E. Cree
Mr. Thomas Czajkowski
Mr. Randy Datsko
Mr. Gene Dawson
Mr. Robert Dean
Mr. Thomas Del Prato
Ms. Dorothy Delarm
Mrs. Julie Dodson Baisinger
Mr. Todd J. Dokken
Mr. Don Douglas and Mrs. Carolyne Douglas
Rich Downen
Dr. Korsi Dumeyno
Mr. and Mrs. Gary Dumnitt
Ms. Sandra Duncan
Dr. Thomas D. Easley
Mr. Willard Easton and Mrs. Joyce Easton
Eden Formulations
Mr. Ehigie Enakhimion
Mr. Kenneth L. English
Dr. John Farnsworth
Mr. Warren Fauver
Mrs. and Mr. Esther Federman
Mr. and Mrs. Daniel J. Feiner
Mr. Ralph Ferrara
Mr. Carlos Ferrer
Mr. Tom Fever
Mr. Greg Fishwick
Dr. Rich Fonda
Mr. and Mrs. Richard Forchetti
Mr. Richard Fournier
Mr. Thomas Frankforter
Mr. Anni Freeman
Mr. Robert Frewing
Mr. Max Fuentes
Mr. Thomas Fuller
Mr. and Mrs. Robert Gain
Mr. Herbert M. Gant
Mr. David A. Gerber
Miss Rose Gilman
Mr. Ryan Gilmartin
Mr. and Mrs. James Gioffe
Mr. Joel Goldberg
Mrs. Joyce Gonzales
Mr. Charles W. Gossett
Mr. Robert Greenbaum and Mrs. Heidi Greenbaum
Mr. Michael D. Grills
Ms. Carmen Hall
Ms. Julie A. Hansen
Mrs. Hope Hare
Mr. David Harvey
Mr. Kent L. Hastings and Mrs. Libby Hastings
Mr. William R. Hasty and Mrs. Sara Hasty
Dr. George Hatch
Ms. Linda Hayes
Mr. and Mrs. John Hazen
Mr. Barry L. Heath
Ms. Corrine Henderson
Mr. Richard Henderson
Mr. David Herndon
Dr. Paul Hesse
Mr. Joseph Hewell
Mr. Jeff Hewitt
Mr. Bradford L. Hillegass
Mr. Nevin Hoke
Mrs. Jody Horwitz
Mr. Robert Horwitz
Mr. Gary House
Mr. Justin Hughes and Mrs. Adrienne Hughes
Mr. Michael R. Hund and Mrs. Linda Hund
Mrs. Christine M. Hunter
Dr. George Hurwitz and Mrs. Karen Hurwitz
Lt. Luke W. Jean
Mr. James Jenkins
Mr. Alfred John
Mr. Randall John
Mr. Dale L. Johnson
Mr. David Johnson and Mrs. Lynda Johnson
Mr. and Mrs. Mark W. Johnson
Mr. Robert A. Johnson and Mrs. Paula Johnson
Mr. Roger A. Jones
Mr. Tom Joplin and Mrs. Shannon Joplin
Dr. Robert R. Jorgensen and Mrs. Dorothy Jorgensen
Mrs. Michael I. Joseph
Mr. Scott Jurgens
Mr. and Mrs. Gary Kasper
David Keitchley
Mr. Damian J. Kelly
Dr. Betty Kennebrew
Mr. Joseph Keyes
Mr. Haydn Kissick
Mr. William D. Kleeman
Mr. Curt Koopman
Mr. Winston Kou
Mrs. Mary Kowalski
Dr. Robert A. Kraft
Mr. and Mrs. Mark Kraus
Mrs. Maureen M. Kuntze
Ms. Sherry Langdon-Crookendale
Mr. Albert Latini and Mrs. Madelaine Latini
Mr. George Lee
Mr. Teng-Kiat Lee
Mrs. Janet Lehoullier
Mr. Steven Leonard-John
Mr. John A. Lever
Mr. Todd Lewandowski and Mrs. Kirsten Lewandowski
Dr. Tom Lewis
Mr. Andrew Lippman
Dr. William Lockhart
Mr. Jack Loeb, Jr.
Dr. Blair Lonsberry
Mr. Robert Lorion
Mr. Garry Louers, Sr.
2019 Research Awards
Expanding PCF’s Global Research Enterprise

PCF YOUNG INVESTIGATOR AWARDS

The achievements of PCF Young Investigators represent some of the most game-changing work in all of cancer research. They keep the field of prostate cancer research vibrant with new ideas. In 2019, PCF funded 30 new Young Investigators. By mid-year 2019, PCF had funded a total of 287 Young Investigators since the program began in 2007, representing $58.2 million in research funding.

2019 National Cancer Institute—PCF Young Investigator Award
Remi Adelaiye-Ogala, PhD
National Cancer Institute (NCI), Bethesda, MD

2019 Meitar-IPMN—PCF Young Investigator Award
Elham Afghani, MD, MPH
Johns Hopkins University, Baltimore, MD

2019 National Cancer Institute—PCF VA lor Young Investigator Award
Mike Beshiri, PhD
National Cancer Institute (NCI), Bethesda, MD

2019 Terry Laughlin and Regina Aldisert—PCF VA lor Young Investigator Award
Mehmet Bilen, MD
Emory University, Atlanta, GA

2019 Greg Brown—PCF Young Investigator Award
James Byrne, MD, PhD
Harvard: Brigham and Women’s Hospital, Boston, MA

2019 Merck/AstraZeneca—PCF Young Investigator Award
Arianna Calcinotto, PhD
Institute of Oncology Research, Bellinzona, Switzerland

2019 Nan and Elliot Abramowitz—PCF Young Investigator Award
Goutam Chakraborty, PhD
Memorial Sloan Kettering Cancer Center, New York, NY

All attendees, representing 18 countries, at the 26th Annual PCF Scientific Retreat on Friday, October 25, 2019
2019 PCF Young Investigator Award Award
Year 1 – Thomas Milana, Jr.
Year 2 – Keith Frankel
Year 3 – Ted Virtue
Catherine Coombs, MD
University of North Carolina, Chapel Hill, NC

2019 Michael and Patricia Berns—PCF Young Investigator Award
Matthew Dallos, MD
Columbia University Medical Center, New York, NY

2019 PCF VAlor Young Investigator Award
Year 1 – Roxann Taylor
Year 2 – Michael DeAddio
Year 3 – Thomas H. Lee
Navonil De Sarkar, PhD
Fred Hutchinson Cancer Research Center, Seattle, WA

2019 PCF Young Investigator Award
Year 1 – Joe Barrata
Year 2 – Tim Connors
Year 3 – Joe Jacobs
Arianna Giacobbe, PhD
Columbia University Medical Center, New York, NY

2019 Young’s Market Company—PCF Young Investigator Award
Gavin Ha, PhD
Fred Hutchinson Cancer Research Center, Seattle, WA

2019 Art Kern and John Paulson—PCF Young Investigator Award
Junjie Tony Hua, PhD
University of California, San Francisco, San Francisco, CA

2019 John Black Charitable Foundation—PCF Young Investigator Award
Anuradha Jayaram, MBBS
University College London Cancer Institute, London, England

2019 Igor Tulchinsky—PCF Young Investigator Award
Janggun Jo, PhD
University of Michigan, Ann Arbor, MI

2019 ASTRO—PCF Career Development Award to End Prostate Cancer
Amar Kishan, MD
University of California, Los Angeles, Los Angeles, CA

2019 PCF VAlor Young Investigator Award
Year 1 – The Citrone 33 Foundation
Year 2 – George Walker
Year 3 – Mark Weinberger
Steven Kregel, PhD
University of Michigan, Ann Arbor, MI

2019 John Black Charitable Foundation—PCF Young Investigator Award
Damien Leach, PhD
Imperial College London, London, England

2019 Larry Leeds—PCF Young Investigator Award
Deli Liu, PhD
Weill Cornell Medicine, New York, NY

2019 PCF Young Investigator Award
Year 1 – Fred Luddy
Year 2 – Andrew Weinberg
Year 3 – Jeremy Coller
Francesca Lorenzin, PhD
Università degli Studi di Trento, Trento, Italy

2019 Republic National Distributing Company (RNDC)—PCF Young Investigator Award
Patrick Pilié, MD
The University of Texas MD Anderson Cancer Center, Houston, TX

2019 Clay Hamlin—PCF Young Investigator Award
Rafaela Pippa, PhD
Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA

2019 Tony D. Minella—PCF Young Investigator Award
Pasquale Rescigno, MD
Institute of Cancer Research, Royal Marsden Hospital, London, England

2019 Igor Tulchinsky—PCF VAlor Young Investigator Award
Jeremy Shelton, MD
University of California, Los Angeles, Los Angeles, CA

2019 Chris and Felicia Evensen—PCF Young Investigator Award
Eugene Shenderov, MD, PhD
Johns Hopkins University, Baltimore, MD

2019 Meitar-IPMN—PCF Young Investigator Award
Lilac Tene, M.Med.Sc.
Maccabi Big Data Center, Tel Aviv, Israel

2019 Eric Klein and Canadian Coalition to Cure Prostate Cancer (CCPC)—PCF Young Investigator Award
Daksh Thaper, PhD
University of British Columbia, Vancouver, BC

2019 Meitar-IPMN—PCF Young Investigator Award
Bo Tu, PhD
Fred Hutchinson Cancer Research Center, Seattle, WA

2019 David Fleischer—PCF Young Investigator Award
Xiao Wei, MD
Harvard: Dana-Farber Cancer Institute, Boston, MA

2019 Progenics Pharmaceuticals—PCF Young Investigator Award
Yukiko Yamaguchi, PhD
City of Hope, Los Angeles, CA
PCF CHALLENGE AWARDS

In 2019, 17 Challenge Award teams were funded by the Foundation. Through peer reviews, PCF selected these projects out of 92 proposals from highly qualified research teams at 58 prestigious cancer centers located in nine countries. The Class of 2019 Challenge Awards represents an investment of nearly $16 million in advanced prostate cancer research.

2019 Movember—PCF Challenge Awards

Co-Principal Investigators:
- John K. Lee, MD, PhD
  Fred Hutchinson Cancer Research Center, Seattle, WA
- Peter Nelson, MD
  University of Washington, Seattle, WA

Goal: To develop and test the clinical efficacy of a novel L1CAM-targeting CAR T cell immunotherapy for the treatment of small cell neuroendocrine prostate cancer

Co-Principal Investigators:
- Eliezer Van Allen, MD
  Harvard: Dana-Farber Cancer Institute, Boston, MA
- Deborah Schrag, MD, MPH
  Harvard: Dana-Farber Cancer Institute, Boston, MA
- Wassim Abida, MD, PhD
  Memorial Sloan Kettering Cancer Center, New York, NY
- Nikolaus Schultz, PhD
  Memorial Sloan Kettering Cancer Center, New York, NY

Goal: To develop digital prostate cancer data platforms that can be used to predict patient outcomes and match patients with optimal precision medicine clinical trials

2019 Movember / Distinguished Gentleman’s Ride—PCF Challenge Award

Principal Investigator:
- Charles Drake, MD, PhD
  Columbia University, New York, NY

Goal: To determine the clinical and biological effects of combining a novel IL-8-targeting immunotherapy, the checkpoint immunotherapy nivolumab, and hormone therapy, in patients with hormone-sensitive recurrent prostate cancer

This Challenge Award has also been co-funded by the Stewart J. Rahr Foundation

2019 PCF Challenge Awards

Co-Principal Investigators:
- Sarki Abdulkadir, MD, PhD
  Northwestern University, Chicago, IL
- Gary Schiltz, PhD
  Northwestern University, Chicago, IL

Goal: To develop a new class of therapies against the critical cancer-promoting gene MYC, for the treatment of prostate cancer and many other types of cancer

Award Donor: Sun Pharma Global FZE (SPGFZE)

Co-Principal Investigators:
- Andrea Alimonti, MD
  Institute of Oncology Research, Bellinzona, Italy
- Johann de Bono, MD, PhD
  Institute of Cancer Research, Royal Marsden Hospital, London, England

Goal: To determine the mechanisms by which myeloid-derived suppressor cells drive prostate cancer growth and test the clinical efficacy of an inhibitor of IL-23, a major tumor-driving protein produced by these cells

Award Donors: Steward J. Rahr Foundation and various other donors

Co-Principal Investigators:
- Gerhardt Attard, MD, PhD
  University College London Cancer Institute, London, England
- Noel Clarke, MBBS
  The Christie NHS Foundation Trust, Manchester, England
- Mahesh Parmar, MSc
  University College London Cancer Institute, London, England

Goal: To develop clinical-grade biomarkers to identify patients with metastatic hormone sensitive prostate cancer who should receive androgen deprivation therapy (ADT) alone vs. ADT + an androgen receptor-targeted therapy

Award Donor: John Black Charitable Foundation

Co-Principal Investigators:
- Johannes Czernin, MD
  University of California, Los Angeles, Los Angeles, CA
- Matthew Rettig, MD
  University of California, Los Angeles, Los Angeles, CA
- Caius Radu, MD
  University of California, Los Angeles, Los Angeles, CA

Goal: To optimize the clinical use of PSMA-targeted radionuclide therapy and identify new combination treatment approaches that overcome therapeutic resistance

Award Donor: Janssen Pharmaceuticals

Co-Principal Investigators:
- Joshua Lang, MD
  University of Wisconsin, Madison, WI
- Steve Cho, MD
  University of Wisconsin, Madison, WI
- David Jarrard, MD
  University of Wisconsin, Madison, WI

Goal: To identify mechanisms and biomarkers of responsiveness of high-risk primary prostate cancers to treatment with docetaxel + hormonal therapy

Award Donors: Herbert V. Kohler and various other donors

Co-Principal Investigators:
- Donald McDonnell, PhD
  Duke University, Durham, NC

Goal: To identify novel treatments and strategies to target the prostate cancer driver HOXB13

Award Donors: Patrice and Precious Motsepe and the Stewart J. Rahr Foundation

Principal Investigator:
- Donald McDonnell, PhD
  Duke University, Durham, NC

Goal: To identify novel treatments and strategies to target the prostate cancer driver HOXB13

Award Donors: Patrice and Precious Motsepe and the Stewart J. Rahr Foundation
Co-Principal Investigators:
Hao Nguyen, MD, PhD
University of California, San Francisco, San Francisco, CA
Peter Carroll, MD, MPH
University of California, San Francisco, San Francisco, CA
Davide Ruggero, PhD
University of California, San Francisco, San Francisco, CA

Goal: To determine the biology by which the gene expression regulators eIF4E and eIF4A drive prostate cancer growth and whether they have potential as therapeutic targets
Award Donors: Michael and Iris Smith, Todd Boehly, John Paulson, and various other donors

Co-Principal Investigators:
Li Xin, PhD
University of Washington, Seattle, WA
Peter Nelson, MD
University of Washington, Seattle, WA
Calvin Kuo, MD, PhD
Stanford University, Stanford, CA

Goal: To identify proteins in the WNT pathway that play role in prostate cancer biology and have potential as therapeutic targets
Award Donors: Patrice and Precious Motsepe, The Citrone 33 Foundation, Fuego Box, Louis Graziaiadio, and various other donors

2019 PCF Valor Challenge Awards
Co-Principal Investigators:
Veda Giri, MD
Thomas Jefferson University, Philadelphia, PA
Stacy Loeb, MD
New York University, New York, NY

Goal: To develop tools to educate physicians, patients and the public on prostate cancer genetics and identify patients who should undergo genetic counseling and testing
Award Donor: Friends of Neal Rodin Philadelphia Home Run Challenge

Co-Principal Investigators:
Salma Kaochar, PhD
Baylor College of Medicine, Houston, TX
Nicholas Mitsiades, MD, PhD
Baylor College of Medicine, Houston, TX

Goal: To determine the potential for targeting master regulators of lipid and cholesterol synthesis as a novel treatment strategy in prostate cancer
Award Donors: Edelman Family Foundation, Jamie Salter, and various other donors

2019 PCF Special Challenge Awards
Principal Investigator:
Michael Hofman, MBBS
Peter MacCallum Cancer Centre, Melbourne, Australia

Goal: To develop a prostate cancer imaging and theranostics centre of excellence that will accelerate clinical development of new prostate cancer theranostics and provide education and leadership to clinicians globally for successful use of these new radioligand and PET imaging technologies in patients
Award Donor: CANICA AS

Co-Principal Investigators:
Alicia Morgans, MD, MPH
Northwestern University, Chicago, IL
Charles Ryan, MD
University of Minnesota, Minneapolis, MN

Goal: To investigate differences in cognitive side effects from treatment with darolutamide vs. enzalutamide in patients and identify risk factors for cognitive impairment
Award Donor: Bayer

Co-Principal Investigators:
Karen Sfanos, PhD
Johns Hopkins University, Baltimore, MD
Tamara Lotan, MD
Johns Hopkins University, Baltimore, MD
Franklin Huang, MD, PhD
University of California, San Francisco, San Francisco, CA

Goal: To determine whether differences in the immune system contribute to prostate cancer incidence and mortality disparities in African American men
Award Donors: Foundation 14, Don Mullen, Neil DeFeo, Michael and Patricia Berns, Estate of Calvin Patterson
# Consolidated Statement of Financial Position

<table>
<thead>
<tr>
<th>December 31</th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>2019 Total</th>
<th>2018 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and Cash Equivalents</td>
<td>$ 9,875,775</td>
<td>$ 3,875,073</td>
<td>$ 13,750,848</td>
<td>$ 20,694,813</td>
</tr>
<tr>
<td>Pledges Receivable (Net)</td>
<td>16,439,127</td>
<td>14,732,927</td>
<td>31,172,054</td>
<td>27,619,136</td>
</tr>
<tr>
<td>Prepaid Expenses and Other Assets</td>
<td>230,858</td>
<td>-</td>
<td>230,858</td>
<td>1,009,073</td>
</tr>
<tr>
<td>Property and Equipment (Net)</td>
<td>1,115,808</td>
<td>-</td>
<td>1,115,808</td>
<td>1,660,133</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td>$ 27,661,568</td>
<td>$ 18,608,000</td>
<td>$ 46,269,568</td>
<td>$ 50,983,155</td>
</tr>
</tbody>
</table>

| **LIABILITIES AND NET ASSETS** |                           |                         |            |            |
| Liabilities |                           |                         |            |            |
| Accounts Payable | $ 591,061 | $ - | $ 591,061 | $ 783,154 |
| Accrued Liabilities | 1,632,070 | - | 1,632,070 | 2,298,474 |
| Deferred Revenue | 30,000 | - | 30,000 | 50,000 |
| Grants Payable | 22,369,031 | - | 22,369,031 | 22,589,282 |
| **Total Liabilities** | 24,622,162 | - | 24,622,162 | 25,720,910 |

| Net Assets |                           |                         |            |            |
| Without Donor Restrictions | 3,039,406 | - | 3,039,406 | 7,887,245 |
| With Donor Restrictions | - | 18,608,000 | 18,608,000 | 17,375,000 |
| **Total Net Assets** | 3,039,406 | 18,608,000 | 21,647,406 | 25,262,245 |

| **Total Liabilities and Net Assets** | $ 27,661,568 | $ 18,608,000 | $ 46,269,568 | $ 50,983,155 |
### Consolidated Statement of Activities

#### Year Ended December 31

<table>
<thead>
<tr>
<th></th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>2019 Total</th>
<th>2018 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue and Public Support</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grants and Contributions</td>
<td>$38,009,305</td>
<td>$7,208,000</td>
<td>$45,217,305</td>
<td>$42,068,134</td>
</tr>
<tr>
<td>Interest and Dividends</td>
<td>$190,896</td>
<td>-</td>
<td>$190,896</td>
<td>$231,741</td>
</tr>
<tr>
<td>Other Loss</td>
<td>(688,762)</td>
<td>-</td>
<td>(688,762)</td>
<td>(274,082)</td>
</tr>
<tr>
<td>Net Assets Released from Donor Restrictions</td>
<td>$5,975,000</td>
<td>(5,975,000)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total Revenue and Public Support</strong></td>
<td>$43,486,439</td>
<td>1,233,000</td>
<td>$44,719,439</td>
<td>$42,026,793</td>
</tr>
</tbody>
</table>

#### Expenses

**Program Services:**

- Research Grants: $29,207,005
- Compensation, Benefits, and Payroll Taxes: $4,515,337
- Global Scientific Conferences, Unpublished Data, and Knowledge Exchanges: $2,174,354
- Outreach, Events, and Meetings: $1,162,163
- Professional Fees: $817,501
- Media, Public Relations, and Publications: $671,813
- Depreciation and Amortization: $476,396
- Travel, Meals, and Entertainment: $335,016
- Office Expenses: $307,675
- Occupancy: $178,532

**Total Program Services:** $39,845,792

**Supporting Services:**

**Management and General:**

- Compensation, Benefits, and Payroll Taxes: $2,031,124
- Office Expenses: $865,440
- Professional Fees: $305,913
- Occupancy: $252,023
- Travel, Meals, and Entertainment: $121,505
- Depreciation and Amortization: $82,940
- Media, Public Relations, and Publications: $55,948

**Total Management and General:** $3,714,893

**Fundraising:**

- Travel, Meals, and Entertainment: $1,545,876
- Outreach, Events, and Meetings: $1,239,406
- Compensation, Benefits, and Payroll Taxes: $1,146,412
- Office Expenses: $385,696
- Professional Fees: $212,591
- Media, Public Relations, and Publications: $197,696
- Occupancy: $31,912
- Depreciation and Amortization: $14,004

**Total Fundraising:** $4,773,593

**Total Expenses:** $48,334,278

#### Change in Net Assets

- Revenue and Public Support: (4,847,839)
- Expenses: (3,614,839)

**Net Assets – End of Year:** $3,039,406
## Consolidated Statement of Cash Flows

<table>
<thead>
<tr>
<th>Year Ended December 31</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in Net Assets</td>
<td>$(3,614,839)</td>
<td>$(3,553,487)</td>
</tr>
<tr>
<td><strong>Adjustments to Reconcile Change in Net Assets to Net Cash Used In Operating Activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in Present Value Discount on Pledges Receivable</td>
<td>(1,005)</td>
<td>415,854</td>
</tr>
<tr>
<td>Depreciation and Amortization</td>
<td>573,340</td>
<td>546,830</td>
</tr>
<tr>
<td>(Increase) Decrease in:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pledges Receivable</td>
<td>$(3,551,913)</td>
<td>$(438,565)</td>
</tr>
<tr>
<td>Prepaid Expenses and Other Assets</td>
<td>778,215</td>
<td>126,861</td>
</tr>
<tr>
<td>Increase (Decrease) in:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts Payable</td>
<td>(192,093)</td>
<td>(536,626)</td>
</tr>
<tr>
<td>Accrued Liabilities</td>
<td>(666,404)</td>
<td>381,769</td>
</tr>
<tr>
<td>Deferred Revenue</td>
<td>(20,000)</td>
<td>(50,000)</td>
</tr>
<tr>
<td>Grants Payable</td>
<td>(220,251)</td>
<td>(23,564)</td>
</tr>
<tr>
<td><strong>Net Cash Provided by (Used In) Operating Activities</strong></td>
<td>$(6,914,950)</td>
<td>$(3,130,928)</td>
</tr>
</tbody>
</table>

**CASH FLOWS USED IN INVESTING ACTIVITIES:**

| Purchase of Property and Equipment | (29,015) | (341,223) |
| **Net Decrease in Cash and Cash Equivalents** | $(6,943,965)| $(3,472,151)|

| Cash and Cash Equivalents – Beginning of Year | 20,694,813 | 24,166,964 |
| **Cash and Cash Equivalents – End of Year** | $13,750,848 | $20,694,813 |
Independent Auditor’s Report

To the Board of Directors
Prostate Cancer Foundation

Report on the Consolidated Financial Statements
We have audited the accompanying consolidated financial statements of the Prostate Cancer Foundation, which comprise the consolidated statement of financial position as of December 31, 2019, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management’s Responsibility for the Consolidated Financial Statements
Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility
Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Prostate Cancer Foundation as of December 31, 2019, and the changes in its consolidated net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Emphasis of Matter
As discussed in Note 10 to the consolidated financial statements, the recent COVID-19 pandemic in the United States and worldwide has resulted in reduced economic activity and market declines. As the extent and duration of the future impact to Prostate Cancer Foundation are uncertain, no adjustments were necessary to the consolidated financial statements, and our opinion is not modified with respect to this matter.

Report on Summarized Comparative Information
We have previously audited Prostate Cancer Foundation’s 2018 consolidated financial statements, and we expressed an unmodified audit opinion on those audited consolidated financial statements in our report dated April 8, 2019. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2018 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

Green Hasson & Janks LLP
May 15, 2020
Los Angeles, California
2019 Supporting Partners

PCF is grateful for our major corporate partners and pharmaceutical company supporters. Contributions, campaigns, and educational initiative funding from these organizations are enabling PCF to move closer to a world without prostate cancer.
# Board of Directors and Leadership Team

## Board of Directors

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Milken</td>
<td>Founder and Chairman</td>
</tr>
<tr>
<td>Prostate Cancer Foundation</td>
<td></td>
</tr>
<tr>
<td>Emilio Bassini</td>
<td>Managing Principal</td>
</tr>
<tr>
<td>Bassini &amp; Company</td>
<td></td>
</tr>
<tr>
<td>James C. Blair, PhD</td>
<td>Partner</td>
</tr>
<tr>
<td>Domain Associates, LLC</td>
<td></td>
</tr>
<tr>
<td>Steven A. Burd</td>
<td>Founder and Chief Executive Officer</td>
</tr>
<tr>
<td>Burd Health LLC</td>
<td></td>
</tr>
<tr>
<td>Neil P. DeFeo</td>
<td>Executive Partner</td>
</tr>
<tr>
<td>Nonantum Capital Partners</td>
<td></td>
</tr>
<tr>
<td>David A. Ederer</td>
<td>Chairman</td>
</tr>
<tr>
<td>Ederer Investment Company</td>
<td></td>
</tr>
<tr>
<td>Jonathan Evans</td>
<td>President</td>
</tr>
<tr>
<td>Evans &amp; Co., LLC</td>
<td></td>
</tr>
<tr>
<td>R. Christian B. Evensen</td>
<td>Managing Partner</td>
</tr>
<tr>
<td>Flintridge Capital Investments, LLC</td>
<td></td>
</tr>
<tr>
<td>Peter T. Grauer</td>
<td>Chairman</td>
</tr>
<tr>
<td>Bloomberg LP</td>
<td></td>
</tr>
<tr>
<td>The Reverend Rosey Grier</td>
<td>Chairman</td>
</tr>
<tr>
<td>Milken Family Foundation</td>
<td></td>
</tr>
<tr>
<td>Stein Erik Hagen</td>
<td>Chairman</td>
</tr>
<tr>
<td>Orkla ASA</td>
<td></td>
</tr>
</tbody>
</table>

## Leadership Team

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan W. Simons, MD</td>
<td>President and</td>
</tr>
<tr>
<td>Chief Executive Officer</td>
<td></td>
</tr>
<tr>
<td>Ralph Finerman</td>
<td>Chief Financial Officer, Treasurer, and</td>
</tr>
<tr>
<td>Secretary</td>
<td></td>
</tr>
<tr>
<td>Howard R. Soule, PhD</td>
<td>Executive Vice President,</td>
</tr>
<tr>
<td>Chief Science Officer</td>
<td></td>
</tr>
<tr>
<td>Stuart Holden, MD</td>
<td>Medical Director</td>
</tr>
<tr>
<td>Paul Villanti</td>
<td>Executive Director, Programs</td>
</tr>
<tr>
<td>Movember Foundation</td>
<td></td>
</tr>
<tr>
<td>Andrew C. von Eschenbach, MD</td>
<td>President, Samaritan Health</td>
</tr>
<tr>
<td>Initiative Inc.</td>
<td>Drug Administration</td>
</tr>
<tr>
<td>Former Commissioner, Food and Drug Administration</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>Former Director, National Cancer Institute</td>
<td>Senior Fellow, Milken Institute</td>
</tr>
<tr>
<td>Kneeland Youngblood, MD</td>
<td>Founding Partner</td>
</tr>
<tr>
<td>Phares Capital Group</td>
<td></td>
</tr>
<tr>
<td>Jeff Zisk</td>
<td>Managing Director</td>
</tr>
<tr>
<td>Surrey Ventures</td>
<td></td>
</tr>
<tr>
<td>Jonathan W. Simons, MD</td>
<td>President and</td>
</tr>
<tr>
<td>Chief Executive Officer</td>
<td></td>
</tr>
<tr>
<td>Ralph Finerman</td>
<td>Chief Financial Officer, Treasurer, and</td>
</tr>
<tr>
<td>Secretary</td>
<td></td>
</tr>
<tr>
<td>Howard R. Soule, PhD</td>
<td>Executive Vice President,</td>
</tr>
<tr>
<td>Chief Science Officer</td>
<td></td>
</tr>
<tr>
<td>Stuart Holden, MD</td>
<td>Medical Director</td>
</tr>
<tr>
<td>Paul Villanti</td>
<td>Executive Director, Programs</td>
</tr>
<tr>
<td>Movember Foundation</td>
<td></td>
</tr>
<tr>
<td>Andrew C. von Eschenbach, MD</td>
<td>President, Samaritan Health</td>
</tr>
<tr>
<td>Initiative Inc.</td>
<td>Drug Administration</td>
</tr>
<tr>
<td>Former Commissioner, Food and Drug Administration</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>Former Director, National Cancer Institute</td>
<td>Senior Fellow, Milken Institute</td>
</tr>
<tr>
<td>Kneeland Youngblood, MD</td>
<td>Founding Partner</td>
</tr>
<tr>
<td>Phares Capital Group</td>
<td></td>
</tr>
<tr>
<td>Jeff Zisk</td>
<td>Managing Director</td>
</tr>
<tr>
<td>Surrey Ventures</td>
<td></td>
</tr>
</tbody>
</table>
In Memory of

David H. Koch

1940–2019

David Koch was one of the world’s most generous philanthropists and a great friend to the Foundation, contributing a **stunning $50 million** to PCF’s cutting-edge prostate cancer research and saving countless lives. Koch served on the Prostate Cancer Foundation Board of Directors from 1995 to 2019.

“David was a partner of ours in philanthropy and research. His contributions to medical research will live on forever; they have and will continue to benefit millions of Americans and others around the world. We will miss his sense of humor, his wisdom, and his insightfulness.”

– Mike Milken
Chairman, Prostate Cancer Foundation